Reported positions
Quarter-end holdings as filed
Explore the full published position list and its source filing. This record excludes the manager’s cash, shorts and non-13(f) assets.
BAKER BROS. ADVISORS LP
A quarter-end snapshot. Filed up to 45 days later, so this page is not current holdings and never a complete portfolio. what a 13F is — and is not ↓ · methodology §13F ↗
Period
$17.4B
reported valuesum of disclosed values for 2026-03-31; 0 positions carry a NULL value and are excluded from the sum, surfaced here rather than folded away
84
positionsALL retained default holdings for this (filer, period), including NULL-value ones
7
new stakespositions with no comparable holding in the prior quarter (kind new), 2026-03-31
9
exitspositions absent from this quarter's filing after being held last quarter (kind exit), 2026-03-31 — inferred from absence, not a sale record
Position changes — into 2026-03-31
by shares · Δ value · filing link · how changes are classified §Positionposition matched across quarters by exact reported CUSIP over a registry gap — producer-reconciled identity, never a name match identity_reconciled_by_cusip | Changethe reported share count is unchanged across the pair, so the position reads as held rather than as a buy or a sell; only builds before this release inferred a direction from the reported value instead classified_by_value · "exit" = absent this quarter: disposed, delisted, under confidential treatment, or reported instead by an affiliated manager — the filing does not say which · change not classifiable: value undisclosed on one side of the quarter pair, or neither shares nor value can classify it · "no change" = the share count is identical in both quarters; the value moved only with price, so the row is mark-to-market and never an add or a trim (Add / New / Trim / Exit / No change) · "no prior" = this filer has no comparable holdings list for the previous quarter on record — a first filing under this registration, or a quarter reported inside an affiliated manager's filing — so the position is not called a new stake | Δ valuederived by Public Filings from the published aggregate; NULL means the source did not disclose a usable value — never zero | Δ shares | Prev value | Curr value | Prev shares | Curr shares | Flags |
|---|---|---|---|---|---|---|---|---|
Incyte Corporation COMposition key pos:16771 · issuer key iss:1169 | add | −$143M | +421 | $3.0B | $2.9B | 30,743,991 | 30,744,412 | |
Insmed Incorporated COM PAR $.01position key pos:15087 · issuer key iss:1181 | add | +$66.1M | +828,365 | $1.1B | $1.2B | 6,592,746 | 7,421,111 | |
Revolution Medicines, Inc. COMposition key pos:15541 · issuer key iss:1842 | add | +$176M | +100,000 | $753M | $929M | 9,455,357 | 9,555,357 | |
Praxis Precision Medicines, Inc. COMposition key pos:11991 · issuer key iss:1748 | add | +$233M | +626,710 | $332M | $565M | 1,126,488 | 1,753,198 | |
GRAIL, Inc. COMposition key pos:13498 · issuer key iss:1037 | add | +$29.7M | +1,943,281 | $178M | $208M | 2,085,333 | 4,028,614 | |
Ionis Pharmaceuticals, Inc. COMposition key pos:12370 · issuer key iss:1221 | add | +$12.0M | +255,886 | $142M | $154M | 1,791,841 | 2,047,727 | |
Roivant Sciences Ltd. SHSposition key pos:18572 · issuer key iss:2604 | trim | +$14.3M | −687,294 | $121M | $135M | 5,555,017 | 4,867,723 | |
IDEAYA Biosciences, Inc. COMposition key sid:sec:prov:f7d48a640772d3aa60939ca4949078c5 · issuer key cusip6:45166A | add | +$6.4M | +327,689 | $125M | $131M | 3,618,826 | 3,946,515 | |
Arrowhead Pharmaceuticals, Inc. COMposition key pos:16618 · issuer key iss:249 | trim | −$19.5M | −182,862 | $144M | $125M | 2,175,645 | 1,992,783 | |
Immatics N.V. SHSposition key sid:sec:prov:8771e17f16590b5bd511978f2a4f7807 · issuer key cusip6:N44445 | trim | −$19.6M | −1,177,401 | $127M | $107M | 12,094,094 | 10,916,693 | |
AbCellera Biologics Inc. COMposition key sid:sec:prov:1bcf5245eb051e3018a085f3acbfd157 · issuer key cusip6:00288U | add | +$11.5M | +2,750,298 | $94.1M | $106M | 27,525,640 | 30,275,938 | |
Crinetics Pharmaceuticals, Inc. COMposition key pos:15866 · issuer key iss:682 | add | +$8.7M | +702,596 | $76.8M | $85.4M | 1,648,869 | 2,351,465 | |
Celcuity Inc. Note 2.75% 8/1/2031position key pos:16258 · issuer key iss:542 | n/c‡u | +$8.3M | — | $66.6M | $74.9M | 30,750,000 | 30,750,000 | change n/cunit mismatch |
Dianthus Therapeutics, Inc. COMposition key pos:18462 · issuer key iss:731 | add | +$39.0M | +62,405 | $32.5M | $71.5M | 789,759 | 852,164 | |
Alumis Inc. COMposition key pos:17057 · issuer key iss:158 | add | +$29.1M | +450,000 | $15.3M | $44.3M | 1,562,500 | 2,012,500 | |
Mirum Pharmaceuticals, Inc. COMposition key pos:12357 · issuer key iss:1485 | new | +$41.2M | +445,975 | $0 | $41.2M | — | 445,975 | |
Enliven Therapeutics, Inc. COMposition key sid:sec:prov:bf437640b37b30ed62d091e5e9de5808 · issuer key cusip6:29337E | add | +$31.3M | +633,785 | $4.2M | $35.5M | 271,406 | 905,191 | |
Design Therapeutics, Inc. COMposition key sid:sec:prov:652160e4f88d5e68e96c8504db5fee2d · issuer key cusip6:25056L | add | +$6.6M | +352,879 | $20.9M | $27.5M | 2,233,099 | 2,585,978 | |
CytomX Therapeutics, Inc. COMposition key sid:sec:prov:16b2967c1b0bb76b6346bfde109e0bb6 · issuer key cusip6:23284F | add | +$5.3M | +725,000 | $18.1M | $23.4M | 4,250,826 | 4,975,826 | |
Disc Medicine, Inc. COMposition key pos:13022 · issuer key iss:741 | add | −$4.4M | +12,607 | $26.8M | $22.4M | 337,050 | 349,657 | |
Immunocore Holdings plc ADSposition key pos:16434 · issuer key iss:1166 | trim | −$58.5M | −1,588,259 | $80.6M | $22.1M | 2,322,656 | 734,397 | |
Evommune, Inc. COM SHSposition key sid:sec:prov:adbff6ad799c41f5a1fe4cddc6ffc42b · issuer key cusip6:30054Y | new | +$19.5M | +847,390 | $0 | $19.5M | — | 847,390 | |
Tectonic Therapeutic, Inc. COMposition key sid:sec:prov:ab98bdc5d9f0946c8554aa4745533ba5 · issuer key cusip6:878972 | trim | −$58.2K | −295,612 | $18.8M | $18.8M | 903,400 | 607,788 | |
Aktis Oncology, Inc. COMposition key pos:11057 · issuer key iss:119 | new | +$17.8M | +996,351 | $0 | $17.8M | — | 996,351 | |
Generate Biomedicines, Inc. COM SHSposition key sid:sec:prov:4a591541501e3e997ba3c8d31dd91fde · issuer key cusip6:370920 | new | +$17.8M | +1,423,602 | $0 | $17.8M | — | 1,423,602 | |
COMPASS Pathways plc SPONSORED ADSposition key sid:sec:prov:88f799da4526ad1ae0a440740a6e9c1b · issuer key cusip6:20451W | new | +$13.0M | +2,344,720 | $0 | $13.0M | — | 2,344,720 | |
BioNTech SE SPONSORED ADSposition key pos:16026 · issuer key iss:380 | trim | −$24.5M | −249,180 | $35.1M | $10.6M | 368,923 | 119,743 | |
Arcus Biosciences, Inc. COMposition key sid:sec:prov:3c51cfeec4a5be695bdb08ebfaa41e00 · issuer key cusip6:03969F | add | +$2.5M | +145,621 | $6.4M | $9.0M | 270,000 | 415,621 | |
Wave Life Sciences Ltd. SHSposition key pos:15162 · issuer key iss:2734 | add | +$115K | +478,575 | $5.8M | $6.0M | 344,063 | 822,638 | |
Eikon Therapeutics, Inc. COMposition key sid:sec:prov:c25b5f9e8c5b977c71e48306567bac3d · issuer key cusip6:282564 | new | +$5.9M | +555,555 | $0 | $5.9M | — | 555,555 | |
Verastem, Inc. COMposition key pos:14035 · issuer key cusip6:92337C | new | +$3.1M | +584,757 | $0 | $3.1M | — | 584,757 | |
Skye Bioscience, Inc. COMposition key sid:sec:prov:6bbcada89a53f0e10561ca531c92b953 · issuer key cusip6:83086J | add | −$119K | +124,605 | $1.1M | $968K | 1,450,638 | 1,575,243 | |
| pos:14079 | exit‡e | −$14.5M | −143,937 | $14.5M | $0 | 143,937 | — | |
| pos:14363 | exit‡e | −$3.3M | −542,539 | $3.3M | $0 | 542,539 | — | |
| pos:15962 | exit‡e | −$22.0M | −2,822,727 | $22.0M | $0 | 2,822,727 | — | |
| pos:16570 | exit‡e | −$63.8M | −2,772,692 | $63.8M | $0 | 2,772,692 | — | |
| pos:18385 | exit‡e | −$38.4M | −950,000 | $38.4M | $0 | 950,000 | — | |
| sid:sec:prov:0e361d30324f107464e8c1d4734fc7e8 | exit‡e | −$21.2M | −2,349,280 | $21.2M | $0 | 2,349,280 | — | |
| sid:sec:prov:5fce931a0d08a913333cc577a5dd8279 | exit‡e | −$1.0M | −1,804,055 | $1.0M | $0 | 1,804,055 | — | |
| sid:sec:prov:adc22e9a1524ab89aa68e69a21eb8d93 | exit‡e | −$3.6M | −475,737 | $3.6M | $0 | 475,737 | — | |
| sid:sec:prov:d12e469a81d64fc16ec26d9812e44d82 | exit‡e | −$55.0K | −22,809 | $55.0K | $0 | 22,809 | — |
21 more changes below.
Mark-to-market only (no share change) · 52
Positions whose share count is identical in both quarters; the value changed with price, not with a decision.
Positionposition matched across quarters by exact reported CUSIP over a registry gap — producer-reconciled identity, never a name match identity_reconciled_by_cusip | Changethe reported share count is unchanged across the pair, so the position reads as held rather than as a buy or a sell; only builds before this release inferred a direction from the reported value instead classified_by_value · "exit" = absent this quarter: disposed, delisted, under confidential treatment, or reported instead by an affiliated manager — the filing does not say which · change not classifiable: value undisclosed on one side of the quarter pair, or neither shares nor value can classify it · "no change" = the share count is identical in both quarters; the value moved only with price, so the row is mark-to-market and never an add or a trim (Add / New / Trim / Exit / No change) · "no prior" = this filer has no comparable holdings list for the previous quarter on record — a first filing under this registration, or a quarter reported inside an affiliated manager's filing — so the position is not called a new stake | Δ valuederived by Public Filings from the published aggregate; NULL means the source did not disclose a usable value — never zero | Δ shares | Prev value | Curr value | Prev shares | Curr shares | Flags |
|---|---|---|---|---|---|---|---|---|
BeOne Medicines Ltd. SPONSORED ADSposition key pos:15255 · issuer key iss:348 | no change | −$60.2M | 0 | $2.7B | $2.6B | 8,799,053 | 8,799,053 | |
Madrigal Pharmaceuticals, Inc. COMposition key pos:15238 · issuer key iss:1407 | no change | −$126M | 0 | $1.2B | $1.1B | 2,141,701 | 2,141,701 | |
ACADIA Pharmaceuticals Inc. COMposition key pos:18889 · issuer key iss:56 | no change | −$191M | 0 | $1.1B | $955M | 42,896,690 | 42,896,690 | |
Celcuity Inc. COMposition key pos:11232 · issuer key iss:542 | no change | +$114M | 0 | $790M | $904M | 7,915,792 | 7,915,792 | |
Kodiak Sciences Inc. COMposition key sid:sec:prov:b6301632224d8122ae8dff0115962cfa · issuer key cusip6:50015M | no change | +$202M | 0 | $557M | $759M | 19,919,186 | 19,919,186 | |
Kymera Therapeutics, Inc. COMposition key pos:13465 · issuer key iss:1310 | no change | +$47.4M | 0 | $674M | $721M | 8,657,242 | 8,657,242 | |
Summit Therapeutics Inc. COMposition key pos:13224 · issuer key iss:2051 | no change | +$53.5M | 0 | $636M | $690M | 36,391,063 | 36,391,063 | |
Rhythm Pharmaceuticals, Inc. COMposition key pos:17607 · issuer key iss:1846 | no change | −$112M | 0 | $600M | $487M | 5,604,483 | 5,604,483 | |
Alkermes plc SHSposition key pos:16418 · issuer key iss:2418 | no change | +$73.9M | 0 | $280M | $354M | 10,012,267 | 10,012,267 | |
Edgewise Therapeutics, Inc. COMposition key pos:12663 · issuer key iss:796 | no change | +$44.0M | 0 | $163M | $207M | 6,575,940 | 6,575,940 | |
Kiniksa Pharmaceuticals International, plc ORD SHS CL Aposition key pos:14218 · issuer key iss:2550 | no change | +$19.5M | 0 | $117M | $136M | 2,826,246 | 2,826,246 | |
Immunovant, Inc. COMposition key sid:sec:prov:c0680e314bfe2d1131f5c3d642c67920 · issuer key cusip6:45258J | no change | −$3.2M | 0 | $139M | $136M | 5,457,881 | 5,457,881 | |
Stoke Therapeutics, Inc. COMposition key sid:sec:prov:3fee4169345e05a49cf14bcc2babfc71 · issuer key cusip6:86150R | no change | +$2.7M | 0 | $106M | $109M | 3,336,697 | 3,336,697 | |
Abivax S.A. SPONSORED ADSposition key pos:13227 · issuer key iss:50 | no change | −$20.6M | 0 | $118M | $97.5M | 875,796 | 875,796 | |
Replimune Group, Inc. COMposition key pos:13385 · issuer key iss:1836 | no change | −$22.9M | 0 | $107M | $84.5M | 11,045,336 | 11,045,336 | |
Nurix Therapeutics, Inc. COMposition key sid:sec:prov:48ac0f50c981e01f7c5af17d58a117cf · issuer key cusip6:67080M | no change | −$16.2M | 0 | $88.4M | $72.2M | 4,658,556 | 4,658,556 | |
Denali Therapeutics Inc. COMposition key sid:sec:prov:8948595df4e56c28a2e8dffed59ee810 · issuer key cusip6:24823R | no change | +$10.0M | 0 | $61.6M | $71.6M | 3,731,695 | 3,731,695 | |
Monte Rosa Therapeutics, Inc. COMposition key sid:sec:prov:3224bd4d4c1e7dd823e99e6304f866c2 · issuer key cusip6:61225M | no change | +$3.3M | 0 | $68.1M | $71.5M | 4,345,736 | 4,345,736 | |
Structure Therapeutics Inc. SPONSORED ADSposition key sid:sec:prov:862b191ccb923fc424f39385b48ce4f8 · issuer key cusip6:86366E | no change | −$30.6M | 0 | $99.6M | $69.0M | 1,432,529 | 1,432,529 | |
Entrada Therapeutics, Inc. COMposition key pos:11501 · issuer key iss:832 | no change | +$11.9M | 0 | $52.1M | $64.0M | 5,072,730 | 5,072,730 | |
Bicycle Therapeutics plc SPONSORED ADSposition key pos:17645 · issuer key iss:368 | no change | −$26.6M | 0 | $77.1M | $50.5M | 10,885,357 | 10,885,357 | |
Spyre Therapeutics, Inc. COMposition key pos:14500 · issuer key iss:82 | no change | +$17.7M | 0 | $32.8M | $50.4M | 1,000,000 | 1,000,000 | |
Rapport Therapeutics, Inc. COMposition key sid:sec:prov:9fd554b76cc510ac236cd887d1f06195 · issuer key cusip6:75383L | no change | +$1.5M | 0 | $46.9M | $48.4M | 1,547,090 | 1,547,090 | |
Viridian Therapeutics, Inc. COMposition key sid:sec:prov:4b145c10f034612809a5ead021971789 · issuer key cusip6:92790C | no change | −$22.8M | 0 | $61.4M | $38.6M | 1,971,678 | 1,971,678 | |
Prelude Therapeutics Inc. COMposition key sid:sec:prov:52a86e73e5ebd8fb9104a71a48f9c42d · issuer key cusip6:74065P | no change | +$5.3M | 0 | $29.4M | $34.6M | 10,123,824 | 10,123,824 | |
DBV Technologies S.A. SPONSORED ADSposition key sid:sec:prov:097fe4205cdb81b5acf642533490216f · issuer key cusip6:23306J | no change | +$2.5M | 0 | $28.0M | $30.5M | 1,461,425 | 1,461,425 | |
Centessa Pharmaceuticals plc SPONSORED ADSposition key pos:18882 · issuer key cusip6:152309 | no change | +$9.9M | 0 | $16.8M | $26.6M | 670,751 | 670,751 | |
Jade Biosciences, Inc. COMposition key sid:sec:prov:3b4a08cf659449a1ac1d2ee41e501b50 · issuer key cusip6:008064 | no change | −$2.3M | 0 | $25.3M | $23.1M | 1,641,137 | 1,641,137 | |
Xenon Pharmaceuticals Inc. COMposition key pos:13384 · issuer key iss:2365 | no change | +$4.9M | 0 | $16.6M | $21.5M | 370,208 | 370,208 | |
Celldex Therapeutics, Inc. COMposition key sid:sec:prov:30f8f229420c7a82ec2ecf2f2f622045 · issuer key cusip6:15117B | no change | +$3.0M | 0 | $18.1M | $21.1M | 665,370 | 665,370 | |
Neurogene Inc. COMposition key sid:sec:prov:2436d0e4b9db5d946b26deb83a717d5e · issuer key cusip6:64135M | no change | −$436K | 0 | $20.4M | $20.0M | 991,691 | 991,691 | |
Contineum Therapeutics, Inc. CL Aposition key sid:sec:prov:05537d56ca21ce3a27a9a933baf06b09 · issuer key cusip6:21217B | no change | +$2.3M | 0 | $16.2M | $18.6M | 1,420,838 | 1,420,838 | |
argenx SE SPONSORED ADRposition key pos:18170 · issuer key iss:242 | no change | −$2.8M | 0 | $21.2M | $18.4M | 25,174 | 25,174 | |
Cerus Corporation COMposition key sid:sec:prov:5acb3fdf8cac3eec6cd20dcb98ac92d0 · issuer key cusip6:157085 | no change | −$2.4M | 0 | $20.6M | $18.2M | 10,008,345 | 10,008,345 | |
Taysha Gene Therapies, Inc. COM SHSposition key pos:14669 · issuer key iss:2095 | no change | −$4.1M | 0 | $22.0M | $17.9M | 4,004,756 | 4,004,756 | |
Sionna Therapeutics, Inc. COMposition key pos:11054 · issuer key iss:1980 | no change | −$420K | 0 | $16.5M | $16.0M | 400,000 | 400,000 | |
Dyne Therapeutics, Inc. COMposition key pos:14578 · issuer key iss:778 | no change | −$1.2M | 0 | $15.9M | $14.7M | 813,449 | 813,449 | |
Xencor, Inc. COMposition key sid:sec:prov:bc17a1945987420f684d9107b41fd336 · issuer key cusip6:98401F | no change | −$3.6M | 0 | $16.9M | $13.3M | 1,102,106 | 1,102,106 | |
Relay Therapeutics, Inc. COMposition key pos:13232 · issuer key iss:1829 | no change | +$1.7M | 0 | $9.8M | $11.5M | 1,160,117 | 1,160,117 | |
Sera Prognostics, Inc. CLASS A COMposition key sid:sec:prov:6af2a0bf15f867d1bff8c7930f134308 · issuer key cusip6:81749D | no change | −$5.1M | 0 | $16.2M | $11.2M | 5,498,170 | 5,498,170 | |
Pharvaris N.V. COMposition key pos:15462 · issuer key iss:2706 | no change | +$188K | 0 | $10.4M | $10.6M | 375,000 | 375,000 | |
MapLight Therapeutics, Inc. COMposition key sid:sec:prov:25db868bd92949401541405f5298734d · issuer key cusip6:56565P | no change | +$1.0M | 0 | $6.4M | $7.4M | 364,705 | 364,705 | |
Absci Corporation COMposition key sid:sec:prov:f3f8f36b088f3feb965b6e5cad32a6e3 · issuer key cusip6:00091E | no change | −$1.0M | 0 | $7.5M | $6.4M | 2,134,803 | 2,134,803 | |
vTv Therapeutics, Inc. CL Aposition key sid:sec:prov:d870181e4209250aa4f0822ee5192029 · issuer key cusip6:918385 | no change | −$48.9K | 0 | $5.9M | $5.9M | 148,314 | 148,314 | |
Protara Therapeutics, Inc. COM STKposition key sid:sec:prov:f702a4fd275ccf1ac7ea45ff5986f07c · issuer key cusip6:74365U | no change | −$117K | 0 | $5.2M | $5.1M | 971,614 | 971,614 | |
Sagimet Biosciences Inc. COM SER Aposition key sid:sec:prov:5e2abdcbdb056fb4d049308ad37d5f46 · issuer key cusip6:786700 | no change | −$662K | 0 | $5.6M | $5.0M | 952,996 | 952,996 | |
LB Pharmaceuticals Inc. COM SHSposition key sid:sec:prov:be515631054470e2500985b7cc1d1245 · issuer key cusip6:50180M | no change | +$480K | 0 | $4.5M | $4.9M | 200,000 | 200,000 | |
TScan Therapeutics, Inc. COMposition key sid:sec:prov:39d93878365e006cfbf0af4c0560d7f2 · issuer key cusip6:89854M | no change | +$27.8K | 0 | $2.8M | $2.8M | 2,784,792 | 2,784,792 | |
Sana Biotechnology, Inc. COMposition key sid:sec:prov:7ff2ed7cd5581a47f16a78be72caca7a · issuer key cusip6:799566 | no change | −$369K | 0 | $1.3M | $894K | 310,483 | 310,483 | |
Aligos Therapeutics, Inc. COMposition key sid:sec:prov:c8979a8455f9af85be7efdcf54e29bb5 · issuer key cusip6:01626L | no change | −$157K | 0 | $774K | $617K | 83,055 | 83,055 | |
Tyra Biosciences, Inc. COMposition key sid:sec:prov:47170149b82e95e4444c881acffa67fc · issuer key cusip6:90240B | no change | +$127K | 0 | $279K | $406K | 10,607 | 10,607 | |
Surrozen, Inc. W EXP 8/11/2026position key sid:sec:prov:c4f97db1890f36f80c7a359d19822318 · issuer key cusip6:86889P | no change | −$3.3K | 0 | $16.7K | $13.3K | 833,333 | 833,333 |
Quarter ended 2026-03-31Newest filing in this build: 2026-07-31. Per-row filing dates are on each receipt.
Changes derive from the aggregate's top-25 slices and keyable positions only; unkeyable holdings are counted in the registry, not differenced. methodology §13F ↗
Book shape
2026-03-31 · concentration · vs tracked median · tick = median- Top-25 concentration
- 91.0%above median 80.0%
- Concentration index
- 761 bpsabove median 446 bps
- Positions with value
- 84 / 84median book 97.5 positions
Concentration uses reported 13F long value, not total assets. The index is withheld when any position lacks a value. Medians are over the 8,748 tracked filers with a 2026-03-31 book; the index median over the 8,662 with a complete book.
null-value positions: 0holdings whose <value> did not parse — retained and counted, never zero-filled · top-N share ·§: 91.0% · HHI (bps) ·§: 761integer Herfindahl–Hirschman index in basis points over disclosed position values · QoQ moves: 93
Filing history
AVAILABLE QUARTERS| Period | Source |
|---|---|
| 2026-03-31 | EDGAR ↗ |
PLANNED sector rotation · Congress overlap · signals for this filer
Complete source filings on SEC EDGAR
The complete filing on EDGAR.
The position list above is served from the published Public Filings build — every position this filer reported for the selected quarter, as it reported it. This block is provenance, not a substitute: the filing itself is the record, and it is one click away. Serving this list is M2-CONTRACT §3, amended 2026-08-02; §3.1 keeps live EDGAR for filings newer than this build.
Open BAKER BROS. ADVISORS LP's 13F filings on SEC EDGAR ↗Notes on this data
Share changes
Compare consecutive quarters
Position changes retain the producer’s classification and comparability flags. Share counts and reported values describe different changes.
Coverage
A snapshot, not current holdings
Use the quarter selector to inspect available periods. Unknown values stay unknown and each table states its coverage.
ViewPrior quarter not yet availableThis build carries one quarter for this manager: 2026-03-31. Notable managers carry four published quarters, others two.
Reported positions — 2026-03-31
1–83 of 83 issuers · $17.4B disclosed value over 84 rows · 0 undisclosed-value rowsEvery row below carries ticker not yet mapped — stated once here rather than repeated on every row.
| KindClassification is not joined into this reported-position view. Use the changed-positions view to compare the two published quarters. | TickerThis list carries reported issuer names and security identities, without a dated ticker mapping. Symbols are not inferred from names. | Issuera position composed from a base filing plus NEW-HOLDINGS amendments keeps every source row here; the composition's latest filed date is the one shown served from this build's published holdings (derived from the filer's own reported rows); every row resolves to its filing | WeightShare of total reported value, calculated only when the full position list has disclosed values. This is 13F long value, not total assets. | Valuevalue undisclosed on the filing: retained and counted, excluded from sums, never shown as $0 | Shares | Position changeShare change is available in the separate comparison view; it is not joined into this position list. | Wt | CongressThe congressional transaction join is unavailable in this build. |
|---|---|---|---|---|---|---|---|---|
| — | INCYverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | Incyte Corporation Incyte Corporation · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $2.9B | 30,744,412 | — | 16.6% | — | |
| — | ONCverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | BeOne Medicines Ltd. BeOne Medicines Ltd. · SPONSORED ADS CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $2.6B | 8,799,053 | — | 15.0% | — | |
| — | INSMverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | Insmed Incorporated Insmed Incorporated · COM PAR $.01 CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $1.2B | 7,421,111 | — | 7.0% | — | |
| — | MDGLverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | Madrigal Pharmaceuticals, Inc. Madrigal Pharmaceuticals, Inc. · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $1.1B | 2,141,701 | — | 6.4% | — | |
| — | CELCverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | Celcuity Inc. | $978M | 38,665,792 | — | 5.6% | — | |
| — | ACADverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | ACADIA Pharmaceuticals Inc. ACADIA Pharmaceuticals Inc. · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $955M | 42,896,690 | — | 5.5% | — | |
| — | RVMDverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | Revolution Medicines, Inc. Revolution Medicines, Inc. · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $929M | 9,555,357 | — | 5.3% | — | |
| — | — | Kodiak Sciences Inc. Kodiak Sciences Inc. · COM CUSIP 50015M109 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $759M | 19,919,186 | — | 4.4% | — | |
| — | KYMRverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | Kymera Therapeutics, Inc. Kymera Therapeutics, Inc. · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $721M | 8,657,242 | — | 4.1% | — | |
| — | SMMTverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | Summit Therapeutics Inc. Summit Therapeutics Inc. · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $690M | 36,391,063 | — | 4.0% | — | |
| — | — | Praxis Precision Medicines, Inc. Praxis Precision Medicines, Inc. · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $565M | 1,753,198 | — | 3.2% | — | |
| — | RYTMverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | Rhythm Pharmaceuticals, Inc. Rhythm Pharmaceuticals, Inc. · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $487M | 5,604,483 | — | 2.8% | — | |
| — | ALKSverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | Alkermes plc Alkermes plc · SHS CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $354M | 10,012,267 | — | 2.0% | — | |
| — | GRALverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | GRAIL, Inc. GRAIL, Inc. · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $208M | 4,028,614 | — | 1.2% | — | |
| — | EWTXverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | Edgewise Therapeutics, Inc. Edgewise Therapeutics, Inc. · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $207M | 6,575,940 | — | 1.2% | — | |
| — | IONSverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | Ionis Pharmaceuticals, Inc. Ionis Pharmaceuticals, Inc. · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $154M | 2,047,727 | — | 0.9% | — | |
| — | — | Kiniksa Pharmaceuticals International, plc Kiniksa Pharmaceuticals International, plc · ORD SHS CL A CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $136M | 2,826,246 | — | 0.8% | — | |
| — | — | Immunovant, Inc. Immunovant, Inc. · COM CUSIP 45258J102 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $136M | 5,457,881 | — | 0.8% | — | |
| — | ROIVverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | Roivant Sciences Ltd. Roivant Sciences Ltd. · SHS CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $135M | 4,867,723 | — | 0.8% | — | |
| — | — | IDEAYA Biosciences, Inc. IDEAYA Biosciences, Inc. · COM CUSIP 45166A102 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $131M | 3,946,515 | — | 0.8% | — | |
| — | — | Arrowhead Pharmaceuticals, Inc. Arrowhead Pharmaceuticals, Inc. · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $125M | 1,992,783 | — | 0.7% | — | |
| — | — | Stoke Therapeutics, Inc. Stoke Therapeutics, Inc. · COM CUSIP 86150R107 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $109M | 3,336,697 | — | 0.6% | — | |
| — | — | Immatics N.V. Immatics N.V. · SHS CUSIP N44445109 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $107M | 10,916,693 | — | 0.6% | — | |
| — | — | AbCellera Biologics Inc. AbCellera Biologics Inc. · COM CUSIP 00288U106 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $106M | 30,275,938 | — | 0.6% | — | |
| — | — | Abivax S.A. Abivax S.A. · SPONSORED ADS CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $97.5M | 875,796 | — | 0.6% | — | |
| — | — | Crinetics Pharmaceuticals, Inc. Crinetics Pharmaceuticals, Inc. · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $85.4M | 2,351,465 | — | 0.5% | — | |
| — | REPLverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | Replimune Group, Inc. Replimune Group, Inc. · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $84.5M | 11,045,336 | — | 0.5% | — | |
| — | — | Nurix Therapeutics, Inc. Nurix Therapeutics, Inc. · COM CUSIP 67080M103 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $72.2M | 4,658,556 | — | 0.4% | — | |
| — | — | Denali Therapeutics Inc. Denali Therapeutics Inc. · COM CUSIP 24823R105 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $71.6M | 3,731,695 | — | 0.4% | — | |
| — | DNTHverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | Dianthus Therapeutics, Inc. Dianthus Therapeutics, Inc. · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $71.5M | 852,164 | — | 0.4% | — | |
| — | — | Monte Rosa Therapeutics, Inc. Monte Rosa Therapeutics, Inc. · COM CUSIP 61225M102 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $71.5M | 4,345,736 | — | 0.4% | — | |
| — | — | Structure Therapeutics Inc. Structure Therapeutics Inc. · SPONSORED ADS CUSIP 86366E106 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $69.0M | 1,432,529 | — | 0.4% | — | |
| — | TRDAverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | Entrada Therapeutics, Inc. Entrada Therapeutics, Inc. · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $64.0M | 5,072,730 | — | 0.4% | — | |
| — | BCYCverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | Bicycle Therapeutics plc Bicycle Therapeutics plc · SPONSORED ADS CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $50.5M | 10,885,357 | — | 0.3% | — | |
| — | — | Spyre Therapeutics, Inc. Spyre Therapeutics, Inc. · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $50.4M | 1,000,000 | — | 0.3% | — | |
| — | — | Rapport Therapeutics, Inc. Rapport Therapeutics, Inc. · COM CUSIP 75383L102 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $48.4M | 1,547,090 | — | 0.3% | — | |
| — | ALMSverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | Alumis Inc. Alumis Inc. · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $44.3M | 2,012,500 | — | 0.3% | — | |
| — | MIRMverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | Mirum Pharmaceuticals, Inc. Mirum Pharmaceuticals, Inc. · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $41.2M | 445,975 | — | 0.2% | — | |
| — | — | Viridian Therapeutics, Inc. Viridian Therapeutics, Inc. · COM CUSIP 92790C104 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $38.6M | 1,971,678 | — | 0.2% | — | |
| — | — | Enliven Therapeutics, Inc. Enliven Therapeutics, Inc. · COM CUSIP 29337E102 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $35.5M | 905,191 | — | 0.2% | — | |
| — | — | Prelude Therapeutics Inc. Prelude Therapeutics Inc. · COM CUSIP 74065P101 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $34.6M | 10,123,824 | — | 0.2% | — | |
| — | — | DBV Technologies S.A. DBV Technologies S.A. · SPONSORED ADS CUSIP 23306J309 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $30.5M | 1,461,425 | — | 0.2% | — | |
| — | — | Design Therapeutics, Inc. Design Therapeutics, Inc. · COM CUSIP 25056L103 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $27.5M | 2,585,978 | — | 0.2% | — | |
| — | — | Centessa Pharmaceuticals plc Centessa Pharmaceuticals plc · SPONSORED ADS CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $26.6M | 670,751 | — | 0.2% | — | |
| — | — | CytomX Therapeutics, Inc. CytomX Therapeutics, Inc. · COM CUSIP 23284F105 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $23.4M | 4,975,826 | — | 0.1% | — | |
| — | — | Jade Biosciences, Inc. Jade Biosciences, Inc. · COM CUSIP 008064206 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $23.1M | 1,641,137 | — | 0.1% | — | |
| — | IRONverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | Disc Medicine, Inc. Disc Medicine, Inc. · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $22.4M | 349,657 | — | 0.1% | — | |
| — | — | Immunocore Holdings plc Immunocore Holdings plc · ADS CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $22.1M | 734,397 | — | 0.1% | — | |
| — | XENEverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | Xenon Pharmaceuticals Inc. Xenon Pharmaceuticals Inc. · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $21.5M | 370,208 | — | 0.1% | — | |
| — | — | Celldex Therapeutics, Inc. Celldex Therapeutics, Inc. · COM CUSIP 15117B202 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $21.1M | 665,370 | — | 0.1% | — | |
| — | — | Neurogene Inc. Neurogene Inc. · COM CUSIP 64135M105 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $20.0M | 991,691 | — | 0.1% | — | |
| — | — | Evommune, Inc. Evommune, Inc. · COM SHS CUSIP 30054Y107 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $19.5M | 847,390 | — | 0.1% | — | |
| — | — | Tectonic Therapeutic, Inc. Tectonic Therapeutic, Inc. · COM CUSIP 878972108 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $18.8M | 607,788 | — | 0.1% | — | |
| — | — | Contineum Therapeutics, Inc. Contineum Therapeutics, Inc. · CL A CUSIP 21217B100 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $18.6M | 1,420,838 | — | 0.1% | — | |
| — | ARGXverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | argenx SE argenx SE · SPONSORED ADR CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $18.4M | 25,174 | — | 0.1% | — | |
| — | — | Cerus Corporation Cerus Corporation · COM CUSIP 157085101 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $18.2M | 10,008,345 | — | 0.1% | — | |
| — | TSHAverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | Taysha Gene Therapies, Inc. Taysha Gene Therapies, Inc. · COM SHS CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $17.9M | 4,004,756 | — | 0.1% | — | |
| — | AKTSverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | Aktis Oncology, Inc. Aktis Oncology, Inc. · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $17.8M | 996,351 | — | 0.1% | — | |
| — | — | Generate Biomedicines, Inc. Generate Biomedicines, Inc. · COM SHS CUSIP 370920100 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $17.8M | 1,423,602 | — | 0.1% | — | |
| — | SIONverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | Sionna Therapeutics, Inc. Sionna Therapeutics, Inc. · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $16.0M | 400,000 | — | 0.1% | — | |
| — | DYNverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | Dyne Therapeutics, Inc. Dyne Therapeutics, Inc. · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $14.7M | 813,449 | — | 0.1% | — | |
| — | — | Xencor, Inc. Xencor, Inc. · COM CUSIP 98401F105 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $13.3M | 1,102,106 | — | 0.1% | — | |
| — | — | COMPASS Pathways plc COMPASS Pathways plc · SPONSORED ADS CUSIP 20451W101 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $13.0M | 2,344,720 | — | 0.1% | — | |
| — | RLAYverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | Relay Therapeutics, Inc. Relay Therapeutics, Inc. · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $11.5M | 1,160,117 | — | 0.1% | — | |
| — | — | Sera Prognostics, Inc. Sera Prognostics, Inc. · CLASS A COM CUSIP 81749D107 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $11.2M | 5,498,170 | — | 0.1% | — | |
| — | BNTXverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | BioNTech SE BioNTech SE · SPONSORED ADS CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $10.6M | 119,743 | — | 0.1% | — | |
| — | PHVSverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | Pharvaris N.V. Pharvaris N.V. · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $10.6M | 375,000 | — | 0.1% | — | |
| — | — | Arcus Biosciences, Inc. Arcus Biosciences, Inc. · COM CUSIP 03969F109 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $9.0M | 415,621 | — | 0.1% | — | |
| — | — | MapLight Therapeutics, Inc. MapLight Therapeutics, Inc. · COM CUSIP 56565P103 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $7.4M | 364,705 | — | 0.0% | — | |
| — | — | Absci Corporation Absci Corporation · COM CUSIP 00091E109 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $6.4M | 2,134,803 | — | 0.0% | — | |
| — | WVEverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | Wave Life Sciences Ltd. Wave Life Sciences Ltd. · SHS CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $6.0M | 822,638 | — | 0.0% | — | |
| — | — | vTv Therapeutics, Inc. vTv Therapeutics, Inc. · CL A CUSIP 918385204 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $5.9M | 148,314 | — | 0.0% | — | |
| — | — | Eikon Therapeutics, Inc. Eikon Therapeutics, Inc. · COM CUSIP 282564103 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $5.9M | 555,555 | — | 0.0% | — | |
| — | — | Protara Therapeutics, Inc. Protara Therapeutics, Inc. · COM STK CUSIP 74365U107 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $5.1M | 971,614 | — | 0.0% | — | |
| — | — | Sagimet Biosciences Inc. Sagimet Biosciences Inc. · COM SER A CUSIP 786700104 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $5.0M | 952,996 | — | 0.0% | — | |
| — | — | LB Pharmaceuticals Inc. LB Pharmaceuticals Inc. · COM SHS CUSIP 50180M108 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $4.9M | 200,000 | — | 0.0% | — | |
| — | — | Verastem, Inc. Verastem, Inc. · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $3.1M | 584,757 | — | 0.0% | — | |
| — | — | TScan Therapeutics, Inc. TScan Therapeutics, Inc. · COM CUSIP 89854M101 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $2.8M | 2,784,792 | — | 0.0% | — | |
| — | — | Skye Bioscience, Inc. Skye Bioscience, Inc. · COM CUSIP 83086J200 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $968K | 1,575,243 | — | 0.0% | — | |
| — | — | Sana Biotechnology, Inc. Sana Biotechnology, Inc. · COM CUSIP 799566104 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $894K | 310,483 | — | 0.0% | — | |
| — | — | Aligos Therapeutics, Inc. Aligos Therapeutics, Inc. · COM CUSIP 01626L204 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $617K | 83,055 | — | 0.0% | — | |
| — | — | Tyra Biosciences, Inc. Tyra Biosciences, Inc. · COM CUSIP 90240B106 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $406K | 10,607 | — | 0.0% | — | |
| — | — | Surrozen, Inc. Surrozen, Inc. · W EXP 8/11/2026 CUSIP 86889P117 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $13.3K | 833,333 | — | 0.0% | — |
1–83 of 83 issuers · page 1 of 1
every row this filer reported for the quarter, as it reported it — cross-filer de-duplication is applied to issuer totals elsewhere and never deletes a row here
A 13F is a quarterly, long-only snapshot filed up to 45 days late — not current holdings. what a 13F covers ↗
13F reports cover LONG positions in Section 13(f) securities (US exchange-traded equities plus reportable options, warrants, certain convertibles) held by managers with at least $100M in such securities — so managers below that threshold are absent entirely. No short positions, no cash, no non-13(f) assets — not a full portfolio, and not a census of institutional ownership.
Positions are quarter-end snapshots filed up to 45 days late — not current holdings. A position may have been changed or closed before you ever see it, and is older still by however long ago that quarter ended.
Values are the manager's stated market value at quarter-end in era-dependent units (whole dollars for form versions effective 2023-01-03 onward, thousands before), normalized here to whole dollars with unit_basis carried on every record.
Affiliated managers may report the same position (otherManager), so one position can appear under more than one filer.
Positions under confidential treatment may be omitted until a later amendment discloses them.
These are disclosures, not investment advice (ARCHITECTURE.md §5.2 / M2-CONTRACT §5).